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A Role for Androgens in Epithelial Proliferation and
Formation of Glands in the Mouse Uterus.
Ioannis Simitsidellis1, Douglas A Gibson1, Fiona L Cousins1,2,
Arantza Esnal-Zufiaurre1, and Philippa TK Saunders1
1 MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, 47 Little France Cres,
EH16 4TJ, Edinburgh, UK
The endometrium consists of stromal and epithelial compartments (luminal and glandular) with
distinct functions in the regulation of uterine homeostasis. Ovarian sex steroids, namely 17-
estradiol (E2) and progesterone (P4), play essential roles in modulating uterine cell proliferation,
stromal-epithelial cross-talk and differentiation in preparation for pregnancy. The impact of an-
drogens on uterine function remains poorly understood. The current study investigated the impact
of the non-aromatizable androgen dihydrotestosterone (DHT) on mouse endometrial function.
Ovariectomized female mice were given a single subcutaneous injection (short treatment) or 7
daily injections (long treatment) of vehicle alone (5% ethanol, 0.4% methylcellulose) or vehicle
with the addition of 0.2 mg DHT (n8/group) and a single injection of Bromodeoxyuridine (BrdU)
2 hours prior to tissue recovery.
Treatment with DHT increased uterine weight, the area of the endometrial compartment and
immunoexpression of the androgen receptor (AR) in the luminal and glandular epithelium. Treat-
ment-dependent proliferation of epithelial cells was identified by immunostaining for MKi67 and
BrdU. Quantitative RT-PCR identified significant DHT-dependent changes in the concentrations of
mRNAs encoded by genes implicated in the regulation of the cell cycle (Wee1, Ccnd1, Rb1) and
stromal-epithelial interactions (Wnt4, Wnt5a, Wnt7a, Cdh1, Vcl, Igf1, Prl8, Prlr) as well as a striking
impact on the number of endometrial glands.
This study has revealed a novel role for androgens in regulating uterine function with an impact
on the glandular compartment of the endometrium. This previously unrecognised role for andro-
gens has implications for our understanding of the role of androgens in regulation of endometrial
function and fertility in women.
The endometrium is a hormone-dependent multicellulartissue that consists of stromal and epithelial compart-
ments. The stromal compartment contains mesenchymal
fibroblasts, a well-developed vasculature and immune
cells, while the epithelium is divided into a luminal and a
glandular component, each with a distinct identity and
role in reproductive physiology (1). Both compartments
respond to hormonal cues in a coordinated spatial and
temporal manner characterized by extensive cross-talk to
regulate the development and homeostasis of the tissue
(2–4).
While the impacts of estrogens on endometrial function
have been extensively studied, androgens have only re-
cently emerged as key players in the regulation of endo-
metrial function. Analysis of circulating steroid hormone
levels utilizing sensitive liquid chromatography-tandem
mass spectrometry has revealed significant concentrations
of androgens present throughout the menstrual cycle in
women exceeding those of circulating estrogens (5). In-
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vestigation of circulating androgen levels in cycling female
mice reported detectable concentrations of the circulating
testosterone metabolite 5-dihydrotestosterone (DHT;
2.8  0.4 pg/ml) during all phases of the estrous cycle, with
concentrations peaking during proestrus and metestrus
(6). In aging female mice, there is a significant increase of
circulating DHT, with a mean value of 12.8  0.6 pg/ml.
To our knowledge there are no studies in the literature
regarding the circulating levels of DHT during mouse
pregnancy, however, there are several reports that andro-
gen levels increase during pregnancy in women (reviewed
in (7)). In women androgens appear to be ‘Goldilocks’
factors with both deficiency and excess contributing to
pregnancy- and fertility-related disorders such as polycys-
tic ovarian syndrome (8, 9), endometriosis (10) and re-
current pregnancy loss (11).
The effects of androgens are mediated via the androgen
receptor (AR), a ligand-activated transcription factor that
binds testosterone (T) and its metabolite 5-dihydrotes-
tosterone (DHT) with high affinity and specificity. In
women, expression of AR in the endometrium is regulated
both temporally and spatially during the normal men-
strual cycle and detailed analysis of full-thickness uterine
tissue sections identified endometrial stromal fibroblasts
as a key targets for androgen action (12). Administration
of antiprogestins in women and nonhuman primates in-
duces upregulation of AR in the uterine epithelium, which
may mediate the antiproliferative effects of these com-
pounds (13). In the uteri of mice, quantitative in situ hy-
bridization detected uniform labeling of Ar mRNA in all
compartments, including the epithelium (14). A recent
study reported nuclear stromal AR staining in the mouse
uterus but AR was not detected in the luminal or glandular
epithelium (15). A study using a transgenic mouse model
of an androgen response element (ARE) construct fused to
a luciferase reporter revealed strong AR activity in the
uterus, with the antiandrogen bicalutamide inhibiting lu-
ciferase activity (16). Female global AR knockout
(ARKO) mice are subfertile, with a neuroendocrine and
ovarian phenotype accompanied by defects in uterine de-
velopment (17).
Studies in female-to-male transsexuals have reported a
negative impact of androgens on endometrial prolifera-
tion in response to long-term administration of testoster-
one, resulting in endometrial atrophy (18, 19). Treatment
of primary human endometrial stromal cells with DHT
also results in a significant reduction in both proliferation
and apoptosis (12). Androgen-estrogen cross-talk has
been implicated in the initiation and progression of endo-
metrial cancers, with androgens acting in an antagonistic
manner to the proliferative effects of estrogens, restricting
endometrial carcinogenesis (reviewed in (20)). Weihua et
al reported that the proliferative effects of E2 in the rat
uterus were blocked by either the antiestrogen tamoxifen
or the antiandrogen flutamide (21), suggesting a func-
tional overlap between androgen and estrogen action in
this rodent species. Microarray analysis of uteri recovered
from ovariectomized mice after a single injection of DHT
revealed time-dependent changes in the expression of
genes involved in the regulation of cell division and organ
development between 12 and 24 hours post injection (22).
Sex steroids have been shown to exert different effects
in cell proliferation and apoptosis resulting from either
acute or chronic stimulation (reviewed in (23, 24)). In the
1970s, Lee and colleagues recorded three phases of epi-
thelial cell proliferation within the mouse uterus in re-
sponse to continuous oral treatment with estrogen, char-
acterized by pronounced uterine epithelial cell
proliferation on days 2 and 3, basal proliferation on days
4 and 5 and a second wave of proliferation on days 19 and
20 (25, 26). Similar effects have been reported in prostate
cancer cells in response to androgen treatment, character-
ized by an early proliferative response followed by a re-
fractory period to androgen-induced proliferation (27).
Taking into account this biphasic effect of androgens in
controlling cell proliferation of target tissues, a short-term
(24 hrs) and a long-term (7 days) treatment paradigm was
selected to elucidate the impact of DHT on endometrial
growth in a mouse model. Experiments were performed in
ovariectomized mice to avoid the confounding impacts of
endogenous ovarian hormones.
In the current study, we show that treatment with DHT
has compartment-specific impacts on the immunoexpres-
sion of AR, cellular proliferation and expression of cell-
cycle regulators and epithelial growth factors resulting in
an increase in the number of uterine glands. These striking
findings identify a novel role for androgens in the regula-
tion of endometrial homeostasis.
Materials and Methods
Animals and Treatments
Female C57BL/6J mice were purchased from Charles Rivers
Laboratories and allowed to acclimate for a week with ad libitum
access to food and water. Mice were maintained in accordance
with UK legal requirements under licensed approval from the UK
Home Office. Eight- to ten-week old female mice were ovariec-
tomized (ovx) by dorsal bilateral ovariectomy and allowed to
recover for 7 days prior to treatment to deplete endogenous sex-
steroid hormones. Surgery was performed under isoflurane an-
esthesia followed by a postoperative analgesic, buprenorphine
(0.1 mg/kg) for pain management. Mice were randomly assigned
into four treatment groups (n  8/group, 32 in total). To explore
the short-term and long-term impacts of androgens mice received
either one (24 hrs group) or seven (7 days group) daily subcu-
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taneous injections of DHT (0.2 mg/mouse) or vehicle control
(5% ethanol-0.4% methylcellulose). Two hours prior to being
sacrificed, mice received an intra-peritoneal injection of 0.1 ml
BrdU (25 mg/ml in PBS).
To measure the serum concentration of DHT after treat-
ments, blood was collected via cardiac puncture and exsangui-
nation from mice treated with VC (5% ethanol-0.4% methyl-
cellulose) or DHT (0.2 mg/mouse) for 24 hrs (n  4/group).
Serum DHT concentrations were assayed using a commercially
available mouse DHT ELISA kit (Amsbio, BlueGene; Cat. Num-
ber E03D0001 - Assay sensitivity: 1 pg/ml). Samples were as-
sayed in duplicate and a standard curve was generated using a
four parameter logistic curve fit (4-PL); sample DHT concentra-
tions were interpolated from the standard curve. For analysis of
tissues, one uterine horn was fixed in 4% neutral buffered for-
malin (NBF) for paraffin embedding, sectioning and histology
while the other horn was kept in RNA Save at –80°C.
RNA Extraction and Reverse Transcription
Total RNA was extracted from homogenized mouse uterine
tissue (20 mg/sample) using TriReagent and chloroform fol-
lowed by RNeasy Mini Kit (Qiagen, UK) column isolation and
elution as per the manufacturer’s instructions. RNA concentra-
tion and quality was measured using a Nanodrop® ND-1000
spectrophotometer (Nanodrop Technologies, USA) and the sam-
ples were standardized to 100ng/l in RNAse-free water. Re-
verse transcription was performed using SuperScript VILO
cDNA Synthesis Kit and Master Mix (Invitrogen, UK) as per the
manufacturer’s instructions using a thermal cycler programmed
at: 25°C for 10 minutes, 42°C for 60 minutes and 52°C for 5
minutes. Two negative controls (no enzyme control and no RNA
control) and one positive control (mouse RNA positive control)
were included for each set of RNA samples.
Quantitative RT-PCR Analysis
Quantitative PCR was performed using SuperMix with Pre-
mixed ROX dye (Invitrogen, UK), primer sets designed using the
Roche Universal Probe Library Assay Design Centre (sequences
in Table 1) purchased from Eurofins (MWG Operon) and probes
from the Roche Universal Probe Library Mouse Set (Roche Ap-
plied Science, UK). Samples were assayed in duplicate and run on
an ABI 7900 HT Fast Real Time PCR machine using the follow-
ing cycling conditions: 95°C for 10 minutes then 40 cycles of
95°C for 15 seconds and 60°C for 1 minute. Primer amplification
efficiency was validated and analysis was performed using the
relative standard curve method. Data were normalized to 18S
and fold-change is expressed as the ratio of expression of each
gene of interest in the treated groups vs the average of the VC
groups (one for the 24 hrs and one for the 7 days time point
respectively). Statistical analysis was performed using GraphPad
Prism 6.0. Data are presented as mean-/SEM. Student’s t test
was used for comparison between VC and DHT groups. Crite-
rion for significance was P  .05. Primer pair and probe infor-
mation is provided in Supplemental Table 1.
Immunohistochemistry and Immunofluorescence
Samples were fixed in 4% NBF overnight at room tempera-
ture, transferred in 70% ethanol and the tissues were processed
for paraffin wax embedding. Transverse sections of 5 m thick-
ness were cut using a microtome (Leica RM2135) and the slides
were incubated overnight at 55°C. For histology, the tissues were
dewaxed, rehydrated and antigen retrieval was performed using
citrate (0.01M citrate, pH 6.0) in a decloaking chamber followed
by several blocking steps with serum from the species the sec-
ondary antibody was raised in, to avoid nonspecific binding and
hydrogen peroxide was used to block endogenous peroxidase
activity. Sections were incubated with the primary antibody di-
luted in serum blocking solution overnight at 4°C. Negative con-
trols were included, in which the primary antibody was omitted
to identify any nonspecific binding by the secondary antibody.
The following day, detection was performed by using either a
conjugated secondary antibody specific for the primary antibody
or a polymer-based detection system (ImmPress, Vector Labs,
UK). For chromogenic immunohistochemistry, DAB (Vector,
UK) was used as a chromogen, while for immunofluorescence the
Tyramide Signal Amplification system (Perkin Elmer, UK) was
used as per the manufacturer’s instructions. Between incuba-
tions, washes were performed with TBS-Tween. Hematoxylin
was used as a counterstain for immunohistochemistry and DAPI
as a counterstain for immunofluorescence. Antibody informa-
tion is provided in Table 1.
Image Acquisition and Stereology
For chromogenic immunohistochemistry images were ac-
quired with a Provis AX70 microscope (Olympus Optical, Lon-
don, UK) fitted with a Canon DS6031 camera (Canon Europe,
Amsterdam) while fluorescent images were acquired with a LSM
710 confocal microscope (Carl Zeiss, UK) and processed with
the ZEN software (Carl Zeiss). Tissue surface area was measured
using a Zeiss AXIO Imager A1 (Carl Zeiss, UK) while quantifi-
cation of BrdU-positive epithelial cells and of the number of
glands was performed by blinded manual counting by two in-
dependent investigators. For the calculation of cell density, sec-
tions were counterstained with DAPI and acquired images were
analyzed using the image analysis software Fiji (28). In all cases,
a minimum of two nonserial sections were used (n  4–8/treat-
Table 1. Antibody Table










Bromodeoxyuridine BrdU Fitzgerald 20-BS17 Sheep polyclonal 1/1000
Marker of proliferation Ki67 MKi17 Abcam Ab15580 Rabbit polyclonal 1/2000
Forkhead box protein 2 FOXA2 Santa
Cruz
SC9187 Goat polyclonal 1/3000
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ment group). Statistical analysis was performed using GraphPad
Prism 6.0. Student’s t test was used for comparison between VC
and DHT groups, with statistical significance for P  .05.
Unless otherwise stated all reagents for this study were pur-
chased from Sigma-Aldrich.
Results
Trophic effects of androgens in the mouse uterus
In order to elucidate the actions of DHT in mouse uter-
ine physiology, ovx mice were treated with either vehicle
or DHT under a short- or long-term treatment regime (24
hrs and 7 days respectively). ELISA analysis of serum from
mice injected with vehicle control or DHT 24 hrs previ-
ously had a mean DHT concentration of 180 pg/ml in the
DHT group, while DHT concentrations in the control
group were below the level of detection (1 pg/ml) (Sup-
plemental Figure 1). These results appear consistent with
those of Zhang et al who previously demonstrated that
ovx C57BL/6 female mice injected subcutaneously with
0.1 mg/mouse DHT, exhibit a peak of circulating DHT 1
hour postinjection (14 ng/ml) which rapidly declines
over the following 24 hrs (29).
The short-term treatment with DHT (24 hrs) induced a
significant increase in uterine weight compared to vehicle
which was further increased when treatment was extended
to 7 days (Figure 1A, P  .001 at 7 days). The effect of
DHT on uterine weight was accompanied by significant
increase of total uterine surface area (Figure 1B), endo-
metrial area (Figure 1C) and myometrial area (Figure 1D)
at both time points. Analysis of cell density suggested the
change in uterine size was due to an increase in cell num-
bers accompanied by a significant reduction in cell density
at both time points (Figure 1E, F).
Treatment with DHT induces epithelial AR
expression in the mouse uterus
Positive immunoexpression of AR was detected in the
stromal compartment at both 24 hrs and 7 days in both
vehicle and DHT-treated mice. DHT treatment induced
expression of AR in the luminal and glandular epithelium
at 24 hrs (Figure 2B) that was absent in vehicle groups at
both time points (Figure 2A, C). In mice treated with DHT
for 7 days, AR was detected in the stroma and the glan-
dular epithelium but not the luminal epithelium (Figure
2D). Real-time PCR showed a significant decrease of Ar
mRNA after 7 days of DHT treatment compared to vehicle
(Figure 2E). Investigation of the expression pattern of ER
revealed no difference between vehicle and DHT treated-
groups at both time points (Supplemental Figure 2).
Treatment with DHT induces epithelial
proliferation in the mouse uterus
Immunofluorescence was performed with an antibody
targeting the proliferation marker MKi67 that detects all
cells in interphase or undergoing mitosis. Staining identi-
fied extensive proliferation of luminal and glandular ep-
ithelial cells after treatment with DHT at 24 hrs compared
to vehicle (Figure 3A, B; white arrowheads). Only a small
number of epithelial cells were positive for MKi67 in both
vehicle- and DHT-treated groups after 7 days of treatment
(Figure 3C, D; white arrowheads). The immunostaining
for MKi67 in the stroma was minimal for all treatment
groups. DHT induced a significant increase of Mki67
mRNA levels after 24 hrs of treatment compared to ve-
hicle, while at 7 days there was no significant change be-
tween the two treatment groups (Figure 3E), consistent
with MKi67 staining detected by immunofluorescence.
DNA incorporation of BrdU was used as a measure of
the proliferative state of cells during the two hours prior to
animal sacrifice. Staining with an anti-BrdU antibody re-
vealed a limited number of positive epithelial cells in the
vehicle-treated groups for both time points (Figure 4A, D).
Treatment with DHT induced extensive proliferation of
both the glandular and luminal epithelium at 24 hrs (Fig-
ure 4B). Very low proliferation was detected in the stromal
compartment. This was also confirmed by assessment of
the proliferation index of epithelial cells; there was a sig-
nificant increase in the proliferation of luminal and glan-
dular epithelial cells between the vehicle and DHT treat-
ment groups at 24 hrs (Figure 4C). That was absent after
7 days (Figure 4D, E, F).
DHT regulates genes necessary for proliferation,
cell-cycle regulation and stromal-epithelial cross-
talk in the mouse uterus
Real-time PCR analysis identified dynamic changes in
the expression of several genes associated with cell-cycle
regulation and stromal-epithelial cross-talk following
treatment with DHT.
Wee1 expression was significantly upregulated by
DHT after 24 hrs, followed by a significant downregula-
tion at 7 days (Figure 5A). Ccnd1 expression was signif-
icantly increased by DHT at 24 hrs followed by a signif-
icant decrease after 7 days (Figure 5B). Rb1 expression
was significantly downregulated by DHT at both time
points (Figure 5C).
Wnt signaling, involved in stromal-epithelial cross-talk
in the uterus, was significantly affected by treatment with
DHT. Wnt4 expression was significantly downregulated
after treatment with DHT for 24 hrs and 7 days (Figure
5D). Wnt5a mRNA concentration was significantly in-
creased by DHT at both time points (Figure 5E), while
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Figure 1. Treatment with DHT induces a trophic effect in the mouse uterus. Mice were ovariectomized and treated with vehicle
control (VC) or DHT as described in the Materials and Methods section. (A) At 24 hrs there was a modest but significant increase in uterine wet
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Wnt7a expression was downregulated by DHT only at 7
days (Figure 5F).
Cdh1 which is expressed in the uterine epithelium was
significantly upregulated by DHT at both 24 hrs and 7
days (Figure 5G), while expression of the adherens junc-
tion component vinculin (Vcl) involved in intercellular ad-
hesion and signaling displayed a significant upregulation
by DHT at 24 hrs, with no significant change observed
between vehicle and DHT at 7 days (Figure 5H). Expres-
sion of the putatively androgen-regulated epithelial
growth factor Igf1 was significantly upregulated by DHT
at both time points compared to vehicle treatments, reach-
ing an average 10-fold increase at 7 days (Figure 5I). Prl8,
whose role has been reported in gland formation in the
mouse uterus, was significantly upregulated more than
20-fold at both time points (Figure 5J), with a similar
pattern observed for it receptor (Prlr, Figure 5J). Further-
more, expression of the epithelial growth factors Fgf7
(Figure 7L) and Hgf (Figure 7M) was significantly altered
after treatment with DHT. The transcription factor
Foxa2, which is exclusively expressed in uterine glands
exhibited a trend for an increase after DHT treatment at
24 hrs (P  .14) but the changes at both time points didn’t
reach statistical significance (Figure 5K).
A role for androgens in regulating gland
formation in the mouse uterus
Histological examination of uterine sections at 7 days
suggested more glands with DHT treatment. FOXA2 is a
transcription factor expressed exclusively in the glands in
the mouse uterus and FOXA2 immunohistochemistry was
performed to quantify the number of glands between the
treatment groups (Figure 6A, B). A significant increase in
the total number of glands was observed with DHT com-
pared to vehicle treatment verifying the qualitative obser-
vations (Figure 6C). To compare the effect of DHT with
that with E2 in glandular expansion, ovx mice treated with
an E2 pellet for a week were used as a comparator. Staining
for FOXA2 and quantification of glands demonstrated
fewer glands in the E2 group compared to the DHT-treated
group accompanied by a weaker staining pattern (Supple-
mental Figure 3A, D). Real-time PCR identified a signif-
icant reduction in Foxa2 expression levels between E2 and
DHT-treated groups (Supplemental Figure 3).
Discussion
In this study, we have demonstrated that androgens induce
epithelial proliferation resulting in an increased numbers
of endometrial glands in the adult mouse uterus. Uterine
glands are essential for uterine receptivity and implanta-
tion and secrete factors which are necessary for the sur-
vival and development of the conceptus. Our results sug-
gest that homeostatic balance of androgens and the local
steroidogenic environment could be important physiolog-
ical drivers of gland formation during endometrial remod-
elling in early pregnancy. Animal models in which uterine
gland development is disrupted, exhibit compromised fer-
tility and altered expression of decidualization factors (30,
31), highlighting the potential for prospective therapeutic
targeting of androgen signaling in the uterus for fertility-
associated disorders (32). Although a trophic effect of an-
drogens in the rodent uterus has previously been reported,
we identify for the first time the molecular mechanisms
involved and selective effects of androgens on distinct tis-
sue compartments within the uterus. Notably, we describe
for the first time that DHT promotes gland formation in
the adult mouse uterus through directly stimulating glan-
dular epithelial proliferation and by driving expression of
regulators of cell cycle and stromal-epithelial interactions.
The novel data generated in the current study provide new
insights into the role of androgens in the regulation of
endometrial function.
In the uterus, sex steroid action occurs via direct steroid
hormone receptor signaling in target cells and indirect
paracrine effects on neighboring cellular compartments.
Such examples of intercellular paracrine signaling include
the stromal-derived secretion of IGF1 and WNT5 bind-
ing on epithelial receptors controlling proliferation and
gland formation respectively. Thus, regulation of the com-
plex stromal-epithelial interactions resulting from andro-
gen action can be investigated using in vivo model systems,
rendering rodents invaluable models. To investigate the
impact of androgen treatment in the steroid-depleted
mouse uterus, we treated ovx mice with DHT at a supra-
physiological dose (0.2 mg/mouse) previously shown to
elicit uterine responses (29, 33). Although the DHT con-
centrations generated in our experimental conditions are
above the physiological levels detected in cycling female
Legend to Figure 1 Continued. . .
weight with DHT treatment while after 7 days of treatment the same effect was more pronounced. (B, C, D) Similar effects for a time-dependent
increase with DHT treatment were observed in total uterine surface area (B) endometrial area (C) and myometrial area (D). (E) Treatment with DHT
resulted in a significant time-dependent decrease in uterine cell density at 24 hrs and 7 days. (F) Representative images of hematoxylin- and eosin-
stained mouse uterine cross-sections after steroid treatments. All error bars represent SEM and Student’s unpaired t test was used for statistical
analysis comparing VC- and DHT-treated samples of the respective time point (n  4–8 per treatment group), *P  .05, **P  .01, ***P  .001,
****P  .0001. Scale bar: 500 m.
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mice (6), this dose is consistent with those used in several
previous studies investigating the direct action of DHT in
the rodent uterus (22, 34) and adipose tissue (29, 35).
In this study, DHT induced a time-dependent increase
in uterine weight in agreement with previous reports in
rats treated with DHT or the synthetic androgen mibo-
lerone, where a dose- and time-dependent increase in uter-
ine weight after androgen treatment was detected in that
species (34). In the present study, increases in total uterine
area, endometrial area and myometrial area accompanied
by a significant decrease in cell density, possibly due to
water imbibition, were detected, demonstrating the
trophic effects of DHT in both uterine compartments in
the mouse. Although trophic effects are also induced by
estrogens in the rodent uterus, in the current study uterine
morphology after DHT treatment lacked the characteris-
tic distended phenotype, edema and thinness of the endo-
metrial layer induced by E2 (36, 37) consistent with a
unique effect of androgens in regulating uterine physiol-
ogy that is distinct from that of estrogens. Early studies
using in vitro cell-free systems and in vivo rodent models
have demonstrated interaction between testosterone and
DHT with ER, leading to nuclear translocation of ER,
while cotreatment with antiestrogens but not antiandro-
gens blocked this effect (38, 39). However, a later study
demonstrated that the in vivo doses of DHT required to
elicit ER cytoplasmic depletion and nuclear translocation
in the rat uterus are very high (5–10 mg), suggesting that
the uterine trophic effects of DHT observed in our study
are unlikely to be mediated by ER (40). In addition, ovari-
ectomized female rats cotreated with
DHT and the AR antagonist bicalu-
tamide exhibited a complete sup-
pression of DHT-induced expres-
sion of Igf1, a growth factor whose
upregulation is both ER- and AR-
controlled (34). This finding to-
gether with the fact that putative
ER target-genes are not induced af-
ter treatment with DHT in the mouse
uterus (34) suggest more of a func-
tional interaction between AR and
ER than a physical one. Notably, in
a study describing the development
of a uterine glandular epithelial spe-
cific ARKO mouse model
(ugeARKO), uterine parameters
(uterine weight and surface area) of
adult ugeARKO female mice were
within the normal range but andro-
gen-induced uterine growth in ovx
mice was impaired (41) consistent
with the results in the present study
which describe androgenic induc-
tion of uterine growth via epithelial
AR.
Since androgens promote growth
of the rodent uterus, we investigated
expression of proliferation markers
in the tissue to elucidate compart-
ment-specific effects. Assessment by
immunofluorecence of the prolifera-
tion marker MKi67 which detects all
actively proliferating cells (cells not
in G0 of the cell-cycle) revealed ex-
tensive proliferation within the uter-
ine epithelium that was associated
Figure 2. Treatment with DHT results in a marked increase of AR
immunoreactivity in uterine epithelial cells accompanied by a downregulation
of Ar mRNA. (A, C) Expression of AR was restricted to the stromal compartment and the
myometrial smooth muscle cells of the vehicle groups at both 24 hrs (A) and 7 days (C) with
glandular (black arrowheads) and luminal epithelial AR levels being low to undetectable. (B, D)
Treatment with DHT resulted in intense AR immunostaining in the stroma accompanied by
expression of AR in the luminal and glandular epithelium after 24 hrs (B, red arrowheads), with
the glandular epithelium retaining AR expression after 7 days of DHT treatment (D). (E)
Treatment with DHT for 7 days resulted in a significant downregulation of Ar mRNA in the
mouse uterus. All error bars represent SEM (n  8 per treatment group), **P  .01. Scale bars:
100 m. Neg: negative control.
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with a significant increase in concentrations of Mki67
mRNA after 24 hours that was also accompanied by nu-
clear translocation of cyclin D1 in the epithelium (data not
shown). The proliferative effect of DHT was confirmed by
assessing incorporation of BrdU, which revealed extensive
proliferation in the epithelial compartment but not in the
stroma after treatment with DHT. Notably, increased pro-
liferation was only detected after 24 hrs of treatment con-
sistent with DHT inducing rapid changes in the tissue. Our
findings are further complemented by Terada et al who
reported that treatment of ovx E2-primed mice with DHT
significantly decreased the apoptotic index of the uterine
epithelium, thus arguing for an inhibitory effect of DHT
on cell death on the mouse uterine epithelium (42). Fur-
thermore, the effects of DHT partially mimic those seen
after treatment with E2 where maximal epithelial prolif-
eration rate is observed after 21 hrs of E2 treatment fol-
lowed by a decline in proliferation and increased apoptosis
after repeated E2 injections (43).
Treatment of ovx mice with DHT resulted in a striking
increase in AR immunoreactivity in the uterine stroma
accompanied by induced expression of AR in glandular
and luminal epithelial cells. Previous
studies have demonstrated that
while androgens decrease AR tran-
scription, they positively modulate
translation efficiency and stability of
the AR protein, thus increasing AR
protein levels (44–47). These find-
ings are in agreement with our data
where we detected a significant de-
crease of Ar mRNA following treat-
ment with DHT for 7 days accom-
panied by an increase of AR protein
levels. As already mentioned, previ-
ous studies have reported that an-
drogenic effects in the mouse uterus
can be mediated via ER signaling
(21, 34), with extensive cross-talk
between the two receptors (40, 48).
However no change was observed in
the expression pattern of ER after
DHT treatment, suggesting that if
any functional interaction occurs be-
tween AR and ER following DHT
treatment it is not due to altered ER
levels.
Taking together the uterine epi-
thelial proliferation following DHT
treatment with the known role of an-
drogens in controlling cell-cycle pro-
gression in the prostate (49) and the
mouse uterus (22), transcript expres-
sion of cell-cycle regulators was an-
alyzed by real-time PCR. The multi-
functional cell-cycle regulator Wee1
controls chromatin integrity and en-
try into mitosis by regulating the
transcription of histones and form-
ing active complexes with factors
that control cell-cycle progression
(reviewed in (50)). DHT induced up-
regulation of Wee1 at 24 hrs, consis-
Figure 3. Short-term treatment with DHT increases MKi67 expression in uterine
epithelial cells. (A, C) VC-treated groups displayed nuclear immunostaining for MKi67 (in
red staining) in a small proportion of epithelial cells (arrowheads indicate MKi67-positive
epithelial cells) at both 24 hrs (A) and 7 days (C). (B) Treatment with DHT for 24 hrs induced
marked expression of MKi67 in the luminal and glandular epithelium, while after 7 days MKi67
staining did not differ from VC-treated groups (D). (E) Real-time PCR revealed a significant
increase in Mki67 mRNA levels after DHT treatment at 24 hrs, with no difference observed at 7
days between vehicle and DHT. LLumen. All error bars represent SEM (n  8 per treatment
group), ****P  .0001. Scale bars: 200 m. Neg: negative control.
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tent with the actively proliferating epithelial compartment
at that time point, while its expression after 7 days of DHT
treatment was significantly reduced compared to vehicle
control suggesting a negative feedback mechanism restor-
ing tissue proliferation to basal levels. The same expres-
sion pattern was observed for Ccnd1 (cyclin D1), whose
levels and nuclear localization have been shown to be reg-
ulated by E2 in mouse uterine epithelial cells (51). Expres-
sion of the cell-cycle inhibitor and tumor suppressor Rb1
was significantly downregulated by DHT at both time
points consistent with increased proliferation and growth
of the uterus detected in response to DHT. Since the
changes seen in uterine size reflect changes in all cellular
compartments (including the stroma) further studies are
required to investigate whether changes in stromal prolif-
eration occur in response to DHT across other time points
post androgen administration. The results of the current
study extend previous transcriptional analyses of samples
generated from DHT-treated isolated human endometrial
stromal cells which demonstrate AR-dependent repres-
sion of cell cycle regulators (52) and DHT-dependent de-
creases in both proliferation and apoptosis (12). Taken
together these results suggest androgens may impact on
the stromal compartment to inhibit stromal cell apoptosis,
rather than promoting proliferation, in addition to the
direct effects on the uterine epithelial proliferation de-
scribed in the current study.
Wnt signaling is a major pathway involved in stromal-
epithelial interactions and organ patterning during neo-
natal and postnatal uterine development. Wnt4 and
Wnt5 are expressed by stromal fibroblasts and Wnt7 by
epithelial cells with paracrine and autocrine signaling con-
trolling cell fate and differentiation of the uterus (53). We
observed significant changes in the expression pattern of
these factors, with Wnt4 and Wnt7a being significantly
downregulated and Wnt5a significantly upregulated after
DHT treatment. Studies with mice have demonstrated that
all three Wnts are required for gland formation in the
uterus and knockout mice for these Wnts have compro-
mised fertility (54–56). In addition, administration of ei-
ther progesterone or the synthetic estrogen diethylstilbes-
trol (DES) during an early postnatal time window inhibits
endometrial formation of glands (adenogenesis) in the
mouse uterus (3, 57). Similarly, cadherin 1 (Cdh1) has
been to shown to be vital for endometrial differentiation
of the uterine epithelium, while loss of Cdh1 in the uterus
leads to absence of glands, a disorganized luminal epithe-
lium and upregulation of Wnt4a with concomitant down-
regulation of Wnt5a in the neonatal mouse uterus (58). In
our study, treatment with DHT induced a significant up-
regulation of Cdh1 at both 24 hrs and 7 days accompanied
by downregulation of Wnt4 and upregulation of Wnt5,
suggesting that androgens in the mouse uterus positively
regulate formation of glands.
Figure 4. DHT stimulates transient epithelial cell proliferation in both glandular and luminal compartments. (A, B) With
VC treatment, BrdU was detected in very few epithelial cells after 24 hrs, while treatment with DHT induced pronounced luminal and glandular
epithelial nuclear BrdU incorporation. (C) Quantification of BrdU-positive cells revealed a significant increase of luminal (LE) and glandular (GE)
epithelial proliferation with DHT after 24 hrs of treatment. (D, E, F) After 7 days of treatment, proliferation index showed no significant difference
between VC and DHT groups. All error bars represent SEM (n  8 per treatment group), ***P  .001, ****P  .0001. Scale bars: 200 m. Neg:
negative control.
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Trophic effects in tissues are often accompanied by tis-
sue remodelling and that led us to investigate the expres-
sion of vinculin (Vcl), an adherens junction component
involved in cell-cell adhesion, whose expression is andro-
Figure 5. Treatment with DHT has time-dependent impacts on concentrations of mRNAs encoded by genes implicated in
regulation of the cell cycle and stroma-epithelial cross-talk. Real-time PCR analysis of whole-tissue uterine homogenates identified
altered expression of cell-cycle regulators and proliferation markers (Wee1 (A), Ccnd1 (B), Rb1 (C)) and genes involved in stroma-epithelial
interactions and epithelial growth factors (Wnt4 (D), Wnt5 (E), Wnt7 (F), Cdh1 (G), Vcl (H), Igf1 (I), Prl8 (J), Prlr (K), Foxa2 (L), Fgf8 (M), Hgf
(N)). For all RT-PCR analyses n  8 per treatment group per time point were used and all data were normalized to the housekeeping gene 18s. All
error bars represent SEM, *P  .05, **P  .01, ***P  .001, ****P  .0001.
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gen-regulated in the prostate (59). Vcl was significantly
upregulated after 24 hrs of DHT treatment and by 7 days
its expression was the same as the vehicle, indicating an
initial phase of alteration in cell adhesion properties fol-
lowed by restoration to basal levels. In addition, this is the
first evidence of androgenic regulation of Vcl in the uterus.
To corroborate the increased epithelial proliferation
after treatment with DHT, expression of epithelial growth
factors was assessed. IGF1 is predominantly produced by
mouse endometrial stromal cells following E2 treatment
and signals to the epithelium to proliferate (51) and pre-
vious studies have reported that the Igf1 promoter con-
tains androgen response elements (60). In the current
study, a significant increase in the expression of the epi-
thelial growth factor Igf1 was detected after 7 days of
DHT treatment. Notably, Nantermet et al reported that
DHT did not induce uterine hypertrophy in mice lacking
a functional estrogen receptor (estrogen receptor  knock-
out mice; ERKO), suggesting that ER is required to me-
diate DHT responses (34). However, Klotz et al have pre-
viously reported that ER expression is necessary to
mediate the proliferative effect of IGF1 in the mouse uterus
(61). Thus, taken together with the data in the current
study these results are consistent with DHT also mediating
indirect effects on proliferation in the uterus through stro-
mal-epithelial cross-talk following induction of the IGF
signaling pathway. The stromal-derived epithelial growth
factors FGF7 and HGF both mediate stromal-epithelial
interactions in the uterus by promoting epithelial prolif-
eration with important roles in epithelial morphogenesis
(62). While progesterone administration in the neonatal
mouse uterus inhibits uterine gland formation accompa-
nied by a significant reduction in the expression of Fgf7
and a significant increase in the expression of Hgf (62), in
our study, treatment with DHT induced the opposite ef-
fect by significantly increasing Fgf7 mRNA levels and de-
creasing Hgf mRNA levels.
The most striking result observed was the impact of
DHT on uterine glands. In control uteri, AR expression
was not detected in glandular epithelial cells, however
DHT treatment induced AR expression and increased
glandular epithelial proliferation. Quantification of
FOXA2-positive glands demonstrated more uterine
glands in the DHT-treated mouse uterus, an effect which
was unique to DHT, as treatment with E2 did not produce
this effect. FOXA2 is expressed exclusively in the uterine
glandular epithelium of mice and Foxa2 uterine knockout
mice fail to develop glands (30). In the current study, DHT
induced changes in expression of a number of factors that
promote adenogenesis in adult mice. Although expression
of Foxa2 mRNA in whole tissue homogenates was not
significantly different between control and DHT treated
mice, treatment with E2 significantly
decreased Foxa2 mRNA concentra-
tions highlighting the importance of
androgen-estrogen balance in the
regulation of this cellular compart-
ment in the uterus. Taken together
these data are consistent with DHT
regulating gland formation in the
adult mouse uterus by inducing a
transcriptional program that results
in de novo adenogenesis.
In the present study, treatment of
mice with DHT revealed androgen-
specific effects on endometrial archi-
tecture characterized by a rapid in-
crease in proliferation of epithelial
cells lining the glands and significant
DHT-dependent changes in expres-
sion of genes associated with cell-cy-
cle regulation and stromal-epithelial
cross-talk. These results suggest that
any endocrine pathology that re-
sulted in significant deviation from
normal intra-tissue concentrations
of androgens could have a long term
impact on the abundance of glandu-
Figure 6. Androgen treatment stimulates the glandular compartment of the
mouse uterus. Immunohistochemistry for the gland-specific transcription factor FOXA2
revealed more glands after DHT treatment (B) compared to VC (A) at 7 days. Quantification of
the glands (C) demonstrated a significant increase in the total number of glands per cross-section
after DHT treatment compared to vehicle. All error bars represent SEM (n  8 per treatment
group), ****P  .0001. Scale bars: 200 m. Neg: negative control.
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lar epithelial cells, with consequent impacts on glandular
secretions and the epithelial-stromal cell cross-talk re-
quired to support establishment of pregnancy in women.
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